A New Zealand scientist is researching a new drug dependence vaccine designed to teach our immune system to reject certain medications before they can trigger highs.
Researchers have been trying unsuccessfully to carry out such an intervention since the 1970s.
Dr. Benjamin Compton believed that the failures were not due to the concept itself, but to the design of the vaccines.
Victoria University's chemistry researcher, who has been involved in the development of immunotherapy treatments for cancer, asthma and influenza, and malaria, aims to create a synthetic vaccine that works in a completely different way than previously tested ,
The New Zealand Drug Foundation reports that 45,000 New Zealanders receive support each year to reduce their alcohol and drug use ̵
The Department of Health estimates the cost of drug damage and interventions at $ 1.8 billion.
Worki Lisa Connor and Compton plan to develop a vaccine platform capable of generating an immune response to small, drug-like compounds.
If successful, the vaccine would avoid the use of protein to activate the immune system.
The ultimate goal is to enable the immune system to recognize a particular drug when it enters the bloodstream and treat it like a toxin.
This means that antibodies bind to the target drug in the periphery and prevent it from "crossing the blood-brain barrier where it normally interacts with receptors and causes a high."
"Achieving this would mean a new paradigm in immunopharmacotherapy," said Compton, who just received a grant of $ 150,000 from the Health Research Council's work.
"And it's important that we develop a vaccine that can be mass-produced cost-effectively."
Vaccines were one of the most cost-effective and effective healthcare interventions Comed said he was able to be vaccinated against drug addiction.
"Ultimately, we're trying to create a robust B-cell response – an antibody response – to specific drug targets." 19659002] Traditionally, this has been achieved by first producing a response from T cells – the white cells that defend us against infections and diseases – which in turn boosted the B cell response. However, due to the complexity of the human body, the generation of the desired T cell response could be difficult.
The cellular processing and presentation of proteins varied from person to person, which may have been partly responsible for the previous failure to develop anti-abuse drug vaccines.
Compton expects its novel vaccine to improve the T cell response, or, even better, directly activate B cells independently of a T cell response.
But even if his vaccine can directly activate B cells, this in itself might not be enough – and that k In order to make this type of vaccine effective, it must be ensured that it also has a memory response to the drug causes.
"We try to understand the simplest way to activate B cells so that we can trigger a memory response to compounds that otherwise would not be recognized by the immune system."
Compton first tested his vaccine Mice, and if he could prove the concept, it could be revolutionary.
"This technology will really be helpful to those addicts who want to rid themselves of their addiction. When this person comes in contact with the drug, a vaccine will ensure that the drug's behavior is not rewarded."
Professor Kath McPherson, Chief Executive of the Health Research Council, said the research is going to be a major issue for the individual and the public health.
"Drug addiction is a serious global problem that not only leads to injury, death and reduced quality of life, but also enormously costs our health care system in hospital admissions and emergency visits, treatment and counseling," she said
A path to the future If Dr. Compton can provide a proof-of-concept, this could be a breakthrough in the development of a vaccine in the future. "
Early detection of cancer
There is another one now the Council's 15 explorer scholarships with a cancer researcher hoping to find an implanted device u that can routinely detect early cancer.
Professor Parry Guilford, an expert in cancer genetics and biology at the University of Otago, has proposed a "dwelling device" that has the potential to transform the survival of cancer.
The device would be introduced into the body and left there for a while to find a new generation of "biomarkers" called the "circulating tumor D" NA or ctDNA.
Not only are these markers able to detect cancer traces with unbelievable specificity, but they can also detect most types of cancer.
However, their sensitivity to modest early disease is modest in the number of ctDNA molecules that can be purified from a standard 8 ml blood collection.
"It works well for late-stage diseases, but lacks the sensitivity to find cancer early when cure by surgery is still possible," Guilford explains.
"We suggest developing a retention device that captures ctDNA more than 36-fold over a 30-minute period so that this technology can routinely detect early-stage cancer."
"We believe this the majority will allow tumors to be diagnosed as long as they are small enough to be healed by surgery. "